CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D006943: Hyperglycemia NIH

(Synonyms: Hyperglycemi, Hyperglycemia)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (1)


Name (Synonyms) Correlation
drug1626 Low-Carbohydrate Diet Wiki 1.00

Correlated MeSH Terms (6)


Name (Synonyms) Correlation
D018149 Glucose Intolerance NIH 1.00
D011236 Prediabetic State NIH 0.71
D004700 Endocrine System Diseases NIH 0.71
D008659 Metabolic Diseases NIH 0.58
D044882 Glucose Metabolism Disorders NIH 0.58
D003920 Diabetes Mellitus, NIH 0.24

Correlated HPO Terms (3)


Name (Synonyms) Correlation
HP:0011998 Postprandial hyperglycemia HPO 1.00
HP:0000818 Abnormality of the endocrine system HPO 0.71
HP:0000819 Diabetes mellitus HPO 0.24

There is one clinical trial.

Clinical Trials


1 Low-Carbohydrate Dietary Pattern on Glycemic Outcomes Trial

The proposed randomized controlled trial will test the effect of a low-carbohydrate diet on hemoglobin A1c among individuals with elevated hemoglobin A1c that are within the range of prediabetes or diabetes. Results may provide evidence about the role of carbohydrate restriction in individuals with or at high risk of type 2 diabetes.

NCT03675360 Diabetes PreDiabetes Metabolic Disease Hyperglycemia Diet Modification Glucose Intolerance Glucose Metabolism Disorders (Including Diabetes Mellitus) Endocrine System Diseases Behavioral: Low-Carbohydrate Diet
MeSH:Diabetes Mellitus Hyperglycemia Prediabetic State Glucose Intolerance Metabolic Diseases Glucose Metabolism Disorders Endocrine System Diseases
HPO:Abnormality of the endocrine system Diabetes mellitus Hyperglycemia Postprandial hyperglycemia

Primary Outcomes

Measure: Change in Hemoglobin A1c

Time: Baseline and six months

Secondary Outcomes

Measure: Change in fasting plasma glucose

Time: Baseline and six months

Measure: Change in systolic blood pressure

Time: Baseline and six months

Measure: Change in total-to-HDL-cholesterol ratio

Time: Baseline and six months

Measure: Change in body weight

Time: Baseline and six months

Other Outcomes

Measure: Change in insulin

Time: Baseline and six months

Measure: Change in homeostasis model assessment of insulin resistance (HOMA-IR)

Time: Baseline and six months

Measure: Change in diastolic blood pressure

Time: Baseline and six months

Measure: Change in waist circumference

Time: Baseline and six months

Description: Based on 10-year cardiovascular disease risk assessed by 2013 American College of Cardiology/American Heart Association Atherosclerotic Cardiovascular Disease Risk Score

Measure: Change in estimated cardiovascular disease risk

Time: Baseline and six months


HPO Nodes